Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 8/20 | 0.62 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.62 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25763179 | 0.98 | KRAS (0.62) | KRASSOS1GPR119IRAK4ADORA2A | |
| SCHEMBL25763594 | 0.96 | KRAS (0.63) | KRASSOS1GPR119IRAK4ADORA2A | |
| SCHEMBL25763585 | 0.95 | KRAS (0.61) | KRASSOS1GPR119ADORA2APIK3CA | |
| SCHEMBL25763596 | 0.95 | KRAS (0.61) | KRASSOS1GPR119OPRM1OPRD1 | |
| SCHEMBL25763196 | 0.94 | KRAS (0.61) | KRASSOS1GPR119ADORA2AOPRM1 | |
| SCHEMBL25763189 | 0.94 | KRAS (0.61) | KRASSOS1GPR119ADORA2AOPRM1 | |
| SCHEMBL25763191 | 0.94 | KRAS (0.61) | KRASSOS1GPR119ADORA2AOPRM1 | |
| SCHEMBL25763175 | 0.93 | KRAS (0.68) | KRASSOS1GPR119ADORA2APIK3CA | |
| SCHEMBL25763198 | 0.93 | KRAS (0.68) | KRASSOS1GPR119ADORA2APIK3CA | |
| SCHEMBL25763599 | 0.93 | KRAS (0.62) | KRASSOS1GPR119ADORA2APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | KRAS 2/4885SOS1 522/4885GPR119 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.